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which they suppress the activation of
conventional T cells has not been eluci-
dated. The observation that suppres-
sion occurs through a soluble factor
should enable biochemical purification
of this inhibitory molecule, a pursuit
that should receive critical attention in
the future. Despite these caveats, the
characterization of the suppressive
effect of TIL-derived gd T cells is an im-
portant observation that expands our
knowledge of the immunosuppressive
activities within the tumor microenvi-
ronment. An overview of key mecha-
nisms is illustrated in Figure 1.
One final consideration is a chicken
and egg issue: Are gd T cells intrinsi-
cally regulatory or do they become so
under the influence of the tumor micro-
environment? TGF-b has been shown
to contribute to the generation of induc-
ible Foxp3+ Treg cells from naive CD4+
conventional T cells, and it is conceiv-
able that regulatory gd T cells could
be induced through a similar mecha-
nism. Assuming that regulatory gd T
cells arise under the condition of
chronic inflammation at tumor sites, it
is possible that they also might be gen-
erated in other situations of chronic
immune stimulation, such as with per-
sistent viral infections. Other immune
suppressive mechanisms at play in
the tumor microenvironment, such as
the expression of PD-L1(B7-H1), the
presence of indoleamine-2,3-dioxyge-
nase, and infiltration with Foxp3+ Treg
cells have indeed been observed to
be prevalent in the situation of chronic
infection, such as inHIV-infected lymph
nodes. A more general role for gd regu-
latory T cells in other in vivo settings will
be of interest to pursue in the future.
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The molecular mechanism of acute lung injury caused by Streptococcus pneumoniae is unclear. In
this issue of Immunity, Lim et al. (2007) demonstrate that CYLD, a deubiquinating enzyme, represses
the expression of plasminogen activator inhibitor-1, which is critical in preventing tissue damage.In Homer’s Odyssey, the protagonist
Odysseus must negotiate his boat
between the multiheaded Scylla and
the whirlpool generating Charybdis or
otherwise succumb to one of these
threats. A similar balance must be
achieved in mucosal immunity: eradi-
cate the offending pathogen without
substantial end-organ injury. Lung in-
fections rank at the top and account
for more than 6% of the total global
burden of disease in 2002 (Mizgerd,
2006). Although antibiotics may im-prove mortality in the setting of lung in-
fections, host immune responses can
also count for substantial disease mor-
bidity and mortality (Mizgerd, 2006).
Understanding the contributions of
specific genes that balance host im-
munity versus organ injury is the first
step in developing rational therapies
to reduce the morbidity and mortality
of lung infections.
In this issue of Immunity, Lim et al.
(2007) demonstrate that the tumor
suppressor CYLD is a critical regulatorImmunityof this balance in the context of pulmo-
nary Streptococcal pneumoniae infec-
tion. CYLD is a deubiquinating enzyme
that was first identified as a tumor sup-
pressor gene and mutations in CYLD
result in the growth of benign cylindro-
mas. Three independent laboratories
showed that CYLD is a negative regu-
lator of the transcription factor NF-kB
by interacting with its signaling com-
ponents IKKg (NEMO) and TRAF2
(Trompouki et al., 2003; Brummel-
kamp et al., 2003; Kovalenko et al.,27, August 2007 ª2007 Elsevier Inc. 187
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Previews2003), and ultimately regulating cellu-
lar susceptibility to apoptosis. Loss of
CYLD activity and therefore loss of
susceptibility to apoptotic stimuli may
be the mechanism of tumor develop-
ment in patients with CYLD mutations.
In addition, CYLD negatively regulates
the antiapoptotic molecule BCL-3, and
Cyld/ mice are more susceptible to
chemically induced tumors (Massoumi
et al., 2006). Two other groups have
generated Cyld/ mice (Reiley et al.,
2006; Zhang et al., 2006). The pheno-
types differ in these two colonies
where one group has observed physi-
cal interactions between CYLD and
the kinase Lck, and deubiquination of
both Lys 48- and Lys 63-linked poly-
ubiquitin chains from Lck resulted in
fewer single positive CD4+ and CD8+
T cells in the periphery (Reiley et al.,
2006). Moreover, this colony demon-
strates spontaneous activation of IkB
kinase b, constitutively active NF-kB
in B cells, B cell hyperplasia, and an in-
crease in marginal zone B cells. In con-
trast, Zhang et al. (2006) reported that
Cyld/ mice generated by deleting
exons 2 and 3 had normal B and T
cell development, but CYLD was a crit-
ical negative regulator of NF-kB and
JNK activation in macrophages in re-
sponse to Toll-like receptor 2 (TLR2),
TLR4, or CD40 agonists. What is clear
from these studies is that CYLD has
activity in myeloid cells of the immune
systems and thus may regulate host
cell immunity in addition to negatively
regulating tumorigenesis. Moreover,
CYLD expression can be induced
by Gram-positive and Gram-negative
bacteria, so Lim et al. (2007) hypothe-
sized that CYLD may regulate host
defenses against bacteria.
By using virulent pneumolysin
(PLY)-expressing S. pneumoniae or
PLY itself, Lim et al. (2007) show that
local lung administration of whole bac-
teria or PLY induces a mortality rate
that was far greater in wild-type mice
compared to Cyld/ mice. Specifi-
cally, Cyld/ mice show less micro-
vascular fluid leak and less hemor-
rhage compared to wild-type mice.
Deficiency in CYLD is associated with
markedly enhanced expression of the
prothrombotic protein plasminogen
activator inhibitor-1 (PAI-1), which is
a member of the serine protease inhib-188 Immunity 27, August 2007 ª2007 Elsitor (serpin) superfamily. To demon-
strate the critical role of PAI-1, the
investigators show that PAI-1 defi-
ciency results in enhanced lung hem-
orrhage induced by S. pneumoniae or
PLY. PAI-1 expression in this model
is controlled by MAP kinase (MAPK) ki-
nase 3 and p38 MAPK, as shown by
the fact that inhibition of p38 MAPK
activation and deficiency of MKK3 re-
duce PAI-1 expression and increase
pulmonary hemorrhage in response
to S. pneumoniae or PLY (Figure 1).
CYLD appears to be a critical link in
this pathway by negatively regulating
phosphorylation of p38 MAPK and
MKK3. Thus, Cyld/ mice show en-
Figure 1. CYLD Regulation of NF-kB and
PAI-1
CYLD can deubiquinate TRAF2 as well as
IKKg and thereby negatively regulate nuclear
translocation of NF-kB. In the study by Lim
et al. (2007), CYLD also represses phosphory-
lation of MKK3 and p38 MAPK, resulting in
negative regulation of PAI-1 expression in re-
sponse to pneumolysin, a TLR4 agonist, or
with S. pneumoniae infection. Whether there
is a direct interaction with CYLD and MKK3
or p38 MAPK remains to be determined. Re-
gardless, absence of CYLD results in aug-
mented MAPK-dependent PAI-1 expression
and reduced lung injury in this model of S.
pneumoniae infection. Although increased
PAI-1 is beneficial in this model of local infec-
tion, global absence of CYLD may potentiate
end organ damage if it results in PAI-1 activa-
tion in systemic sepsis.evier Inc.hanced phosphorylation of these pro-
teins. Pharmacologic inhibition of the
p38 MAPK-MKK3 pathway reduces
PAI-1 expression and enhances mor-
tality inS.pneumoniae-infectedCyld/
mice.
Although the current study shows
that CYLD regulates PAI-1 and tissue
injury in bacterial pneumonia by modu-
lating the amount of phosphorylated
MKK3 and p38 MAPK, the molecular
mechanisms underlying MAPK phos-
phorylation by CYLD remains unclear.
Is this through direct interaction with
these proteins or through deubiquina-
tion of upstream kinases in this path-
way such as MLK-3? Alternatively,
CYLD could be required for deubiqui-
nation of TRAF2. Although the data
with p38 MAPK inhibition clearly sug-
gest that downstream PAI-1 expres-
sion and enhanced survival in the
S. pneumoniae infection model is
p38 MAPK dependent, there may be
PA1-1-independent mechanisms that
contribute to the increased survival
in Cyld/ mice. For example, it would
be important to determine whether
Cyld/ mice have enhanced natural
antibody against S. pneumoniae,
a product of marginal zone B cells.
To date, nearly all in vivo data re-
garding CYLD deficiency in the con-
text of infection is at the whole animal
level, so it is still unclear whether the
enhanced survival is due to CYLD de-
ficiency in specific cells such as mye-
loid or nonmyeloid cells, as both cells
can produce PAI-1 in the lung. Al-
though alveolar macrophages may be
a major source of PAI-1 and NF-kB
signaling, it has recently been demon-
strated that epithelial cell Rel A is
important in host defense against
S. pneumoniae (Quinton et al., 2007).
The cellular distribution of CYLD activ-
ity will be important to be determined if
one wishes to inhibit CYLD or activate
the p38 MAPK pathway as a treatment
for severe pneumonia, because under-
standing the cellular targets for ther-
apy will be critical for the success of
pharmacological manipulation of this
pathway. Furthermore, PAI-1 activity
contributes to thrombosis and organ
dysfunction in sepsis (Russell, 2006),
and therefore targeting this pathway
in pneumonia would need to proceed
with this in mind and perhaps in only
Immunity
Previewsspecific patient subgroups that have
a lower risk of sepsis such as unilobar
pneumonia. Thus, the navigation of
this pathway will need to proceed,
much like our protagonist, with a level
of precision that prevents the whole
ship from going down.
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